(Q46290681)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

title

Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

1 reference

Theodosios D. Filippatos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Christos Rizos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Moses Elisaf

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

K G Lagos

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

V Tsimihodimos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

I F Gazi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

A D Tselepis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

D P Mikhailidis

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

28 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

9-16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

cites work

The metabolic syndrome

1 reference

12 December 2020

Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.

1 reference

12 December 2020

PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme

1 reference

12 December 2020

Prevention and treatment of the metabolic syndrome.

1 reference

12 December 2020

Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma

1 reference

12 December 2020

Multiple actions of high-density lipoprotein

1 reference

12 December 2020

Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome

1 reference

12 December 2020

Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria

1 reference

12 December 2020

Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase

1 reference

12 December 2020

Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects

1 reference

12 December 2020

Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity

1 reference

12 December 2020

The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome

1 reference

12 December 2020

Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.

1 reference

12 December 2020

Do we need to consider inflammatory markers when we treat atherosclerotic disease?

1 reference

12 December 2020

Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis

1 reference

12 December 2020

HDL cholesterol: physiology, pathophysiology, and management

1 reference

12 December 2020

HDL, its enzymes and its potential to influence lipid peroxidation.

1 reference

12 December 2020

Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity

1 reference

12 December 2020

Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles

1 reference

12 December 2020

Glycation impairs high-density lipoprotein function

1 reference

12 December 2020

Alterations in lipoprotein defense against oxidative stress in metabolic syndrome

1 reference

12 December 2020

High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics

1 reference

12 December 2020

Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial

1 reference

12 December 2020

Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2

1 reference

12 December 2020

High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study

1 reference

12 December 2020

Evaluation of methods for the measurement of low-density lipoprotein cholesterol.

1 reference

12 December 2020

Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects

1 reference

12 December 2020

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

1 reference

12 December 2020

HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men

1 reference

12 December 2020

Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase

1 reference

12 December 2020

Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins

1 reference

12 December 2020

Change in alpha1 HDL concentration predicts progression in coronary artery stenosis

1 reference

12 December 2020

High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport

1 reference

12 December 2020

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

1 reference

12 December 2020

Evaluation of selected parameters of the antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation

1 reference

12 December 2020

Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome

1 reference

12 December 2020

Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus

1 reference

12 December 2020

Antiatherogenic small, dense HDL--guardian angel of the arterial wall?

1 reference

12 December 2020

Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy

1 reference

12 December 2020

Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus

1 reference

12 December 2020

Plasma markers of endothelial dysfunction in type 2 diabetics

1 reference

12 December 2020

The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome

1 reference

12 December 2020

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

1 reference

12 December 2020

Association of C-reactive protein, interleukin-1 receptor antagonist and adiponectin with the metabolic syndrome

1 reference

12 December 2020

Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia

1 reference

12 December 2020

Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study

1 reference

12 December 2020

A long and winding road: defining the biological role and clinical importance of paraoxonases

1 reference

12 December 2020

Paraoxonase and coronary heart disease

1 reference

12 December 2020

10.1007/S11745-008-3251-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18956219%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference